Hopp til innhold
NHI.no
Annonse

Primær skleroserende kolangitt: Prognosen

Innhold i artikkelen

Primær skleroserende kolangitt vil kunne føre til skrumplever (levercirrhose). Dette er en tilstand hvor leverens funksjoner opphører, og transplantasjon vil være nødvendig. Det er også økt risiko for å utvikle en krefttype i leveren kalt kolangiokarsinom. Jevnlige kontroller på sykehus er derfor viktige slik at eventuelle forverringer kan oppdages tidlig og behandles.

Annonse

Hos de fleste utvikler denne sykdommen seg svært langsomt. Selv om sykdommen kan være livstruende, vil de fleste kunne leve normalt og det meste av tiden merke lite eller ingenting til sykdommen.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Primær skleroserende kolangitt . Referanselisten for dette dokumentet vises nedenfor

  1. Kowdley KV. Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis. UpToDate, last updated May 21, 2018. UpToDate
  2. Gan SI. Primary sclerosing cholangitis. BestPractice, last updated Feb 17, 2017. bestpractice.bmj.com
  3. Bergquist A, Said K, Broome U. Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand J Gastroenterol 2007;42:88-93. PubMed
  4. Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99-103. PubMed
  5. Bergquist A, Montgomery SM, Bahmanyar S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008;6:939-943. PubMed
  6. Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World J Gastroenterol 2008; 14: 3350-9. PubMed
  7. Lindor KD, Kowdley KV, Harrison ME, American College of Gastroenterology. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol 2015; 110:646. PubMed
  8. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-78. PubMed
  9. Angulo P, Peter JB, Gershwin ME, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000; 32:182. PubMed
  10. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 2008; 48:598. PubMed
  11. Kowdley KV. Primary sclerosing cholangitis in adults: Management. UpToDate, last updated Nov 25, 2019. UpToDate
  12. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-14. PubMed
  13. Tischendorf JJ, Hecker H, Krüger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol 2007; 102:107. PubMed
  14. Navaneethan U, Venkatesh PG, Lashner BA, et al. The Impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2012 March.
  15. Ngu JH, Gearry RB, Wright AJ, Stedman CA. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011; 9:1092. PubMed
Annonse
Annonse